What factors influence SAB Biotherapeutics, Inc. stock price forecasts?

Our analysis considers financial metrics, sector trends, market sentiment, technical indicators, and macroeconomic factors.

Eintragen

Herzlich willkommen!

Mein Konto
Abmeldung

SAB Biotherapeutics, Inc. (SABS) Aktienprognose 2025 - KI-Preisvorhersage & Analyse

SAB Biotherapeutics, Inc. (SABS) AI-Aktienkursprognose & Investitionsanalyse

Letzte Analyse Datum: Juli 18, 2025

Loading SAB Biotherapeutics, Inc. interaktives Kursdiagramm und technische Analyse...

SAB Biotherapeutics, Inc. (SABS) - Umfassende Aktienanalyse & Investment Research

Deep dive into SAB Biotherapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about SAB Biotherapeutics, Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

Für SAB Biotherapeutics, Inc.: SAB Biotherapeutics, Inc. operates in the Life Sciences sector, making it an emerging small-cap investment.

SAB Biotherapeutics, Inc. (Börsenkürzel: SABS) ist ein führendes Unternehmen in der Life Sciences Branche die speziell in der Branche Biological Products, (No Diagnostic Substances) tätig sind.

Die Organisation beschäftigt weltweit etwa 81 Fachkräfte .

Das Unternehmen hat sich etabliert als eine aufstrebende Investitionsmöglichkeit mit erheblichem Wachstumspotenzial.

Understanding Financial Performance

Was diese Metriken bedeuten: Key financial indicators showing SAB Biotherapeutics, Inc.'s revenue scale, profitability, market value, and shareholder returns.

Wie man sie liest: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

Für SAB Biotherapeutics, Inc.:

Marktkapitalisierung: $24 Millionen - Einstufung als Small-Cap-Anlage mit hohem Wachstumspotenzial.

Eigenkapitalrendite (ROE): -42,6% - Unterdurchschnittlich Effizienz der Aktionärsrendite, was darauf hindeutet Bereiche für operative Verbesserungen.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for SAB Biotherapeutics, Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Accuracy scores show historical prediction reliability.

Für SAB Biotherapeutics, Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Premium-KI-Vorhersagen freischalten um auf unsere fortschrittlichen Machine-Learning-Prognosen für die SAB Biotherapeutics, Inc.-Aktie zuzugreifen, einschließlich 7-Tage-, 30-Tage- und 90-Tage-Kurszielen mit Konfidenzintervallen und Risikoeinschätzungen.

Understanding Market Position

What this analysis covers: SAB Biotherapeutics, Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

Für SAB Biotherapeutics, Inc.: Market positioning analysis based on available financial and operational metrics.

SAB Biotherapeutics, Inc. konkurriert strategisch auf dem hochdynamischen Biological Products, (No Diagnostic Substances) marktplatz, eine aufstrebende Small-Cap-Investition mit erheblichem Wachstumspotenzial und der Fähigkeit, den Markt zu verändern .

Das Unternehmen weist eine gesunde 9,1% Bruttomarge auf, was auf eine starke Preissetzungsmacht und betriebliche Effizienz hindeutet.

SAB Biotherapeutics, Inc. (SABS) Fundamentalanalyse & Insiderhandelsdaten (Vierteljährliche Finanzberichte)

Umfassende vierteljährliche Finanzdaten, Gewinntrends, Insidertransaktionen und institutionelle Beteiligungen für SAB Biotherapeutics, Inc. Aktienanalyse.

Loading SAB Biotherapeutics, Inc. umfassende Fundamentalanalyse und Insiderhandelsdaten...

Tiefe Einblicke in die finanzielle Gesundheit, die Bewertungskennzahlen und die betriebliche Effizienz von SAB Biotherapeutics, Inc., um fundierte Investitionsentscheidungen zu treffen.

Bewertungsmetriken verstehen

Was diese Metriken bedeuten: Mit Hilfe von Bewertungskennzahlen lässt sich feststellen, ob eine SAB Biotherapeutics, Inc.-Aktie im Vergleich zu ihren Erträgen, Vermögenswerten und ihrer Marktposition einen fairen Preis hat.

Wie man sie liest: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

Für SAB Biotherapeutics, Inc.: Bei einem Kurs-Gewinn-Verhältnis von -2,28 ist der Markt hält die Aktie für potenziell unterbewertet.

P/E Ratio -2,28x

P/B Ratio 1,12x

Market Cap $24M

EPS $-2,55

Buchwert/Aktie $2,30

Umsatz/Aktie $0,30

Rentabilitätsmetriken verstehen

Was diese Metriken bedeuten: Diese Kennzahlen messen, wie effizient SAB Biotherapeutics, Inc. Einnahmen in Gewinn umwandelt und Renditen für die Aktionäre erwirtschaftet.

Wie man sie liest: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

Für SAB Biotherapeutics, Inc.: Eine Eigenkapitalrendite von -42,6% zeigt Raum für Verbesserungen bei Wertschöpfung für die Aktionäre.

ROE -42,6%

ROA -26,0%

ROIC -36,3%

Gross Margin 9,1%

Operating Margin -8909,9%

Net Margin -6592,4%

EBT Margin 21,5%

Finanzielle Gesundheitsmetriken verstehen

Was diese Metriken bedeuten: Diese Kennzahlen bewerten die Fähigkeit von SAB Biotherapeutics, Inc., kurzfristigen Verpflichtungen nachzukommen und den Schuldenstand effektiv zu verwalten.

Wie man sie liest: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

Für SAB Biotherapeutics, Inc.: Ein aktuelles Verhältnis von 1,98 eine angemessene Liquidität aufweist.

Current Ratio 1,98x

Quick Ratio 1,87x

D/E Ratio 0,12x

Financial Leverage 1,64x

Interest Coverage -59,0x

Cashflow-Metriken verstehen

Was diese Metriken bedeuten: Die Cashflow-Kennzahlen geben Aufschluss über die Fähigkeit von SAB Biotherapeutics, Inc., Mittel aus dem operativen Geschäft zu generieren und Wachstumsinitiativen zu finanzieren.

Wie man sie liest: Ein positiver operativer Cashflow ist entscheidend. Der freie Cashflow zeigt, wie viel Geld für Dividenden, Rückkäufe oder Investitionen zur Verfügung steht.

Für SAB Biotherapeutics, Inc.: Freier Cashflow von $-26M weist auf Bargeldprobleme hin, die Aufmerksamkeit erfordern.

Operating Cash Flow $-16M

Free Cash Flow $-26M

Capital Spending $-10M

FCF/Sales -4,6%

CapEx/Sales 20,8%

Metriken für die betriebliche Effizienz verstehen

Was diese Metriken bedeuten: Diese Kennzahlen messen, wie effektiv SAB Biotherapeutics, Inc. sein Vermögen einsetzt und das Betriebskapital verwaltet.

Wie man sie liest: Höhere Umschlagshäufigkeiten deuten auf eine effiziente Nutzung der Vermögenswerte hin. Kürzere Inkassofristen zeigen ein effizientes Kreditmanagement.

Für SAB Biotherapeutics, Inc.: Ein Vermögensumschlag von 1,45x demonstriert Effizienz Anlagennutzung.

Asset Turnover 1,45x

Receivables Turnover 4,6x

Fixed Assets Turnover 3,0x

Offene Verkaufstage 80 Tage

Verstehen von Jahresabschlussdaten

Was diese Metriken bedeuten: Schlüsselzahlen aus der Gewinn- und Verlustrechnung und der Bilanz von SAB Biotherapeutics, Inc., die die absolute finanzielle Leistung zeigen.

Wie man sie liest: Die Einnahmen zeigen die Größe des Unternehmens, während die Gewinnspannen die Rentabilität anzeigen. Die Bilanzposten geben Aufschluss über die Finanzstruktur.

Für SAB Biotherapeutics, Inc.:

Gewinn- und Verlustrechnung ($ Millionen)

Betriebseinkommen $-51M

Reingewinn $-45M

F&E-Ausgaben $27M

SG&A-Aufwand $13M

Highlights der Bilanz (% Of Assets)

Total Current Assets 54%

Cash & Short-term Investments 33%

Total Liabilities 39%

Short-term Debt 0%

Accounts Receivable 17%

Informationen zu Dividende und Aktionären

Shares Outstanding 9M

Wachstumsmetriken (YoY)

EPS Growth -60,0%

Neueste SAB Biotherapeutics, Inc. Aktiennachrichten und Marktanalysen

Aktuelle Nachrichten, Analystenberichte und Marktaktualisierungen, die den Aktienkurs und die Investitionsaussichten von SAB Biotherapeutics, Inc. (SABS) betreffen.

SAB Biotherapeutics to Present at INNODIA Annual Meeting

1y ago, Quelle: Seeking Alpha

MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (SABS) (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy ...

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

10d ago, Quelle: Yahoo Finance

SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a ...

SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations

2y ago, Quelle: Seeking Alpha

A replay of the webcast will be made available on the SAB website following the event. About SAB Biotherapeutics, Inc. Certain statements made herein that are not historical facts are forward-looking ...

SAB Biotherapeutics To Advance SAB-142 Into Phase 2b Trials After Positive Phase 1 Results

7mon ago, Quelle: Nasdaq

(RTTNews) - SAB Biotherapeutics Inc. (SABS), a clinical-stage biopharmaceutical company, on Tuesday announced positive topline data from its Phase 1 trial of SAB-142, a potential disease-modifying ...

SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

1mon ago, Quelle: Nasdaq

SAB Biotherapeutics, Inc. (SABS) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus ...

Here’s Why SAB Biotherapeutics, Inc. (NASDAQ:SABS) Is Among the Best Diabetes Stocks to Buy Under $10

8mon ago, Quelle: Insider Monkey

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at where SAB Biotherapeutics, Inc. (NASDAQ:SABS) stands against the other ...

SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

1y ago, Quelle: WDAF-TV

Australian Human Research Ethics Committee (HREC) grants approval for SAB to begin first-in-human Phase 1 clinical study of SAB-142, the first fully human anti-thymocyte immunoglobulin (ATG) SAB-142 ...

SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes

1y ago, Quelle: ksn.com

Funding will support development of SAB-142, a potential disease-modifying therapy for type 1 diabetes and other autoimmune conditions Participating investors include Sessa Capital, BVF Partners, RTW ...

Q1 EPS Forecast for SAB Biotherapeutics Boosted by Analyst

5mon ago, Quelle: ETF Daily News

SAB Biotherapeutics, Inc. (NASDAQ:SABS – Free Report) – HC Wainwright lifted their Q1 2025 earnings estimates for SAB Biotherapeutics in a research note issued on Tuesday, April 1st. HC Wainwright ...

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the ...

10d ago, Quelle: None

SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing ...

SAB Biotherapeutics, Inc. Wettbewerber und Peer-Analyse - Life Sciences Sektor

Vergleichende Analyse von SAB Biotherapeutics, Inc. mit Branchenkollegen und Wettbewerbern im Life Sciences-Sektor, mit KI-gestützten Prognosen und wichtigen Finanzkennzahlen.

Unternehmen	Ticker-Symbol	90-Tage-Prognose für AI	Marktkapitalisierung (USD Mio.)	Kurs-Gewinn-Verhältnis	P/B-Verhältnis
Acumen Pharmaceuticals, Inc.	ABOS	Unlock Forecast - 30 Days FREE Trial	$85M	-1,9x	0,7x
Abpro Holdings, Inc.	ABP	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
Abpro Holdings, Inc.	ABPWW	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
Arcellx, Inc.	ACLX	Unlock Forecast - 30 Days FREE Trial	$3725M	-74,1x	8,9x
Alpha Cognition Inc.	ACOG	Unlock Forecast - 30 Days FREE Trial	$143M	x	4,5x
Adaptimmune Therapeutics PLC	ADAP	Unlock Forecast - 30 Days FREE Trial	$65M	-13,2x	-11,8x
ADMA BIOLOGICS, INC.	ADMA	Unlock Forecast - 30 Days FREE Trial	$3959M	19,0x	9,9x
Adaptive Biotechnologies Corp	ADPT	Unlock Forecast - 30 Days FREE Trial	$1918M	-4,6x	10,7x
Adverum Biotechnologies, Inc.	ADVM	Unlock Forecast - 30 Days FREE Trial	$58M	-1,8x	2,2x
AGENUS INC	AGEN	Unlock Forecast - 30 Days FREE Trial	$130M	-0,5x	-0,5x
AIM ImmunoTech Inc.	AIM	Unlock Forecast - 30 Days FREE Trial	$2M	-0,5x	-183,3x
AIM ImmunoTech Inc.	AIMI	Unlock Forecast - 30 Days FREE Trial	$2M	x	x
Alector, Inc.	ALEC	Unlock Forecast - 30 Days FREE Trial	$305M	-1,2x	4,3x
Aligos Therapeutics, Inc.	ALGS	Unlock Forecast - 30 Days FREE Trial	$107M	-19,2x	1,1x
Allogene Therapeutics, Inc.	ALLO	Unlock Forecast - 30 Days FREE Trial	$253M	-1,4x	0,7x
Kalaris Therapeutics, Inc.	ALVR	Unlock Forecast - 30 Days FREE Trial	$49M	-0,5x	0,4x
AMGEN INC	AMGN	Unlock Forecast - 30 Days FREE Trial	$149527M	22,6x	20,1x
Apogee Therapeutics, Inc.	APGE	Unlock Forecast - 30 Days FREE Trial	$2160M	-20,5x	4,3x
Aptose Biosciences Inc.	APTO	Unlock Forecast - 30 Days FREE Trial	$6M	0,0x	-1,3x
Aptose Biosciences Inc.	APTOF	Unlock Forecast - 30 Days FREE Trial	$3M	x	x
Armata Pharmaceuticals, Inc.	ARMP	Unlock Forecast - 30 Days FREE Trial	$103M	-1,0x	-1,6x
Artiva Biotherapeutics, Inc.	ARTV	Unlock Forecast - 30 Days FREE Trial	$88M	x	0,6x
Athira Pharma, Inc.	ATHA	Unlock Forecast - 30 Days FREE Trial	$15M	-0,2x	0,5x
Atara Biotherapeutics, Inc.	ATRA	Unlock Forecast - 30 Days FREE Trial	$149M	25,8x	-1,1x
aTYR PHARMA INC	ATYR	Unlock Forecast - 30 Days FREE Trial	$515M	-3,6x	6,9x
Aura Biosciences, Inc.	AURA	Unlock Forecast - 30 Days FREE Trial	$384M	-4,9x	2,2x
Autolus Therapeutics plc	AUTL	Unlock Forecast - 30 Days FREE Trial	$367M	x	1,1x
ANAVEX LIFE SCIENCES CORP.	AVXL	Unlock Forecast - 30 Days FREE Trial	$800M	-17,3x	8,8x
BioAtla, Inc.	BCAB	Unlock Forecast - 30 Days FREE Trial	$125M	-1,1x	1,0x
BioCardia, Inc.	BCDA	Unlock Forecast - 30 Days FREE Trial	$12M	-0,6x	-7,8x
BRAINSTORM CELL THERAPEUTICS INC.	BCLI	Unlock Forecast - 30 Days FREE Trial	$7M	-4,9x	-0,9x
BIOCRYST PHARMACEUTICALS INC	BCRX	Unlock Forecast - 30 Days FREE Trial	$1802M	-12,1x	-4,0x
Black Diamond Therapeutics, Inc.	BDTX	Unlock Forecast - 30 Days FREE Trial	$171M	11,8x	1,3x
Beam Therapeutics Inc.	BEAM	Unlock Forecast - 30 Days FREE Trial	$2076M	-12,6x	2,0x
BIOGEN INC.	BIIB	Unlock Forecast - 30 Days FREE Trial	$18125M	12,8x	1,5x
Black Hawk Acquisition Corp	BKHA	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
Black Hawk Acquisition Corp	BKHAU	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
bluebird bio, Inc.	BLUE	Unlock Forecast - 30 Days FREE Trial	$49M	-0,2x	-0,8x
Cabaletta Bio, Inc.	CABA	Unlock Forecast - 30 Days FREE Trial	$155M	-1,6x	0,9x
Candel Therapeutics, Inc.	CADL	Unlock Forecast - 30 Days FREE Trial	$338M	-4,6x	4,5x
C4 Therapeutics, Inc.	CCCC	Unlock Forecast - 30 Days FREE Trial	$193M	-2,6x	1,1x
Cidara Therapeutics, Inc.	CDTX	Unlock Forecast - 30 Days FREE Trial	$728M	-1,0x	5,1x
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.	CELZ	Unlock Forecast - 30 Days FREE Trial	$9M	-3,4x	1,3x
CERO THERAPEUTICS HOLDINGS, INC.	CERO	Unlock Forecast - 30 Days FREE Trial	$2M	x	-196,2x
CERO THERAPEUTICS HOLDINGS, INC.	CEROW	Unlock Forecast - 30 Days FREE Trial	$2M	x	-0,5x
Cullinan Therapeutics, Inc.	CGEM	Unlock Forecast - 30 Days FREE Trial	$449M	-4,1x	0,8x
COMPUGEN LTD	CGEN	Unlock Forecast - 30 Days FREE Trial	$134M	x	2,7x
CG Oncology, Inc.	CGON	Unlock Forecast - 30 Days FREE Trial	$2542M	x	3,8x
COGNITION THERAPEUTICS INC	CGTX	Unlock Forecast - 30 Days FREE Trial	$170M	-0,5x	24,1x
Pelthos Therapeutics Inc.	CHRO	Unlock Forecast - 30 Days FREE Trial	$8M	x	-2,0x
Coherus Oncology, Inc.	CHRS	Unlock Forecast - 30 Days FREE Trial	$150M	0,8x	1,3x
Calidi Biotherapeutics, Inc.	CLDI	Unlock Forecast - 30 Days FREE Trial	$5M	-0,9x	3,1x
Compass Therapeutics, Inc.	CMPX	Unlock Forecast - 30 Days FREE Trial	$494M	-4,8x	5,3x
Coeptis Therapeutics Holdings, Inc.	COEPW	Unlock Forecast - 30 Days FREE Trial	$M	x	x
Caribou Biosciences, Inc.	CRBU	Unlock Forecast - 30 Days FREE Trial	$174M	-1,5x	1,1x
Cardiff Oncology, Inc.	CRDF	Unlock Forecast - 30 Days FREE Trial	$144M	-4,0x	2,5x
CARGO Therapeutics, Inc.	CRGX	Unlock Forecast - 30 Days FREE Trial	$215M	x	0,9x
CURIS INC	CRIS	Unlock Forecast - 30 Days FREE Trial	$18M	-0,3x	-2,9x
CRISPR Therapeutics AG	CRSP	Unlock Forecast - 30 Days FREE Trial	$4972M	-12,1x	2,9x
CHAMPIONS ONCOLOGY, INC.	CSBR	Unlock Forecast - 30 Days FREE Trial	$111M	-17,8x	20,4x
CEL SCI CORP	CVM	Unlock Forecast - 30 Days FREE Trial	$56M	-0,9x	8,0x
Cyclo Therapeutics, Inc.	CYTH	Unlock Forecast - 30 Days FREE Trial	$26M	-0,6x	-1,9x
Cyclo Therapeutics, Inc.	CYTHW	Unlock Forecast - 30 Days FREE Trial	$7M	x	-0,5x
DBV Technologies S.A.	DBVT	Unlock Forecast - 30 Days FREE Trial	$1479M	-3,3x	514,8x
Ginkgo Bioworks Holdings, Inc.	DNA	Unlock Forecast - 30 Days FREE Trial	$568M	-13,9x	0,3x
Denali Therapeutics Inc.	DNLI	Unlock Forecast - 30 Days FREE Trial	$2111M	-8,7x	1,9x
PRECISION BIOSCIENCES INC	DTIL	Unlock Forecast - 30 Days FREE Trial	$59M	-2,2x	1,7x
DYADIC INTERNATIONAL INC	DYAI	Unlock Forecast - 30 Days FREE Trial	$28M	-7,3x	11,4x
Editas Medicine, Inc.	EDIT	Unlock Forecast - 30 Days FREE Trial	$231M	-0,8x	3,7x
Elevation Oncology, Inc.	ELEV	Unlock Forecast - 30 Days FREE Trial	$22M	-1,0x	0,5x
ELUTIA INC.	ELUT	Unlock Forecast - 30 Days FREE Trial	$84M	-1,4x	-0,1x
enGene Holdings Inc.	ENGN	Unlock Forecast - 30 Days FREE Trial	$292M	3,7x	1,5x
enGene Holdings Inc.	ENGNW	Unlock Forecast - 30 Days FREE Trial	$37M	x	0,1x
Entera Bio Ltd.	ENTX	Unlock Forecast - 30 Days FREE Trial	$94M	8,5x	5,4x
ENZO BIOCHEM INC	ENZ	Unlock Forecast - 30 Days FREE Trial	$25M	-3,0x	0,5x
ENZO BIOCHEM INC	ENZB	Unlock Forecast - 30 Days FREE Trial	$37M	x	0,8x
Estrella Immunopharma, Inc.	ESLA	Unlock Forecast - 30 Days FREE Trial	$39M	-3,1x	-16,9x
Estrella Immunopharma, Inc.	ESLAW	Unlock Forecast - 30 Days FREE Trial	$4M	x	5,3x
EXELIXIS, INC.	EXEL	Unlock Forecast - 30 Days FREE Trial	$11208M	18,6x	5,5x
EXOZYMES INC.	EXOZ	Unlock Forecast - 30 Days FREE Trial	$100M	x	13,9x
FATE THERAPEUTICS INC	FATE	Unlock Forecast - 30 Days FREE Trial	$115M	-1,3x	0,4x
4D Molecular Therapeutics, Inc.	FDMT	Unlock Forecast - 30 Days FREE Trial	$406M	-3,0x	1,0x
FENNEC PHARMACEUTICALS INC.	FENC	Unlock Forecast - 30 Days FREE Trial	$250M	1758,3x	-39,7x
Finch Therapeutics Group, Inc.	FNCH	Unlock Forecast - 30 Days FREE Trial	$20M	-0,1x	1,4x
FutureTech II Acquisition Corp.	FTII	Unlock Forecast - 30 Days FREE Trial	$-26M	x	-0,7x
FutureTech II Acquisition Corp.	FTIIU	Unlock Forecast - 30 Days FREE Trial	$-26M	x	-0,8x
FutureTech II Acquisition Corp.	FTIIW	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
GILEAD SCIENCES, INC.	GILD	Unlock Forecast - 30 Days FREE Trial	$143989M	22,8x	7,3x
Monte Rosa Therapeutics, Inc.	GLUE	Unlock Forecast - 30 Days FREE Trial	$399M	16,5x	1,5x
Genenta Science S.p.A.	GNTA	Unlock Forecast - 30 Days FREE Trial	$64M	x	5,1x
Green Planet Bio Engineering Co. Ltd.	GPLB	Unlock Forecast - 30 Days FREE Trial	$M	x	x
HALOZYME THERAPEUTICS, INC.	HALO	Unlock Forecast - 30 Days FREE Trial	$9647M	17,3x	29,0x
HilleVax, Inc.	HLVX	Unlock Forecast - 30 Days FREE Trial	$105M	-0,6x	0,7x
Humacyte, Inc.	HUMA	Unlock Forecast - 30 Days FREE Trial	$224M	-3,3x	55,2x
Humacyte, Inc.	HUMAW	Unlock Forecast - 30 Days FREE Trial	$163M	x	-2,6x
ImmunityBio, Inc.	IBRX	Unlock Forecast - 30 Days FREE Trial	$2427M	-3,6x	-4,1x
Ikena Oncology, Inc.	IKNA	Unlock Forecast - 30 Days FREE Trial	$61M	-1,3x	0,5x
Inhibikase Therapeutics, Inc.	IKT	Unlock Forecast - 30 Days FREE Trial	$150M	-1,0x	1,9x
Immunocore Holdings plc	IMCR	Unlock Forecast - 30 Days FREE Trial	$1775M	x	4,6x
Immunovant, Inc.	IMVT	Unlock Forecast - 30 Days FREE Trial	$2764M	-14,5x	4,5x
IN8BIO, INC.	INAB	Unlock Forecast - 30 Days FREE Trial	$21M	-0,4x	2,4x
Inhibrx Biosciences, Inc.	INBX	Unlock Forecast - 30 Days FREE Trial	$426M	-6,8x	6,2x
MiNK Therapeutics, Inc.	INKT	Unlock Forecast - 30 Days FREE Trial	$59M	-1,5x	-1,4x
Inmune Bio, Inc.	INMB	Unlock Forecast - 30 Days FREE Trial	$52M	-2,5x	1,8x
INTENSITY THERAPEUTICS, INC.	INTS	Unlock Forecast - 30 Days FREE Trial	$7M	-2,2x	3,4x
IOVANCE BIOTHERAPEUTICS, INC.	IOVA	Unlock Forecast - 30 Days FREE Trial	$776M	-4,5x	1,1x
Century Therapeutics, Inc.	IPSC	Unlock Forecast - 30 Days FREE Trial	$44M	-0,7x	0,2x
iTeos Therapeutics, Inc.	ITOS	Unlock Forecast - 30 Days FREE Trial	$393M	-2,8x	0,7x
Invivyd, Inc.	IVVD	Unlock Forecast - 30 Days FREE Trial	$137M	-0,4x	3,2x
EXOZYMES INC.	IZTC	Unlock Forecast - 30 Days FREE Trial	$99M	x	-27,5x
Jasper Therapeutics, Inc.	JSPR	Unlock Forecast - 30 Days FREE Trial	$44M	-3,2x	1,9x
Jasper Therapeutics, Inc.	JSPRW	Unlock Forecast - 30 Days FREE Trial	$3M	x	0,0x
Kalaris Therapeutics, Inc.	KLRS	Unlock Forecast - 30 Days FREE Trial	$86M	x	1,6x
Klotho Neurosciences, Inc.	KLTO	Unlock Forecast - 30 Days FREE Trial	$26M	x	2,4x
Klotho Neurosciences, Inc.	KLTOW	Unlock Forecast - 30 Days FREE Trial	$1M	x	0,4x
Kodiak Sciences Inc.	KOD	Unlock Forecast - 30 Days FREE Trial	$489M	-2,5x	7,0x
Kiromic Biopharma, Inc.	KRBPQ	Unlock Forecast - 30 Days FREE Trial	$0M	x	x
Krystal Biotech, Inc.	KRYS	Unlock Forecast - 30 Days FREE Trial	$4284M	29,2x	4,1x
Kymera Therapeutics, Inc.	KYMR	Unlock Forecast - 30 Days FREE Trial	$3773M	-17,8x	3,9x
Kyverna Therapeutics, Inc.	KYTX	Unlock Forecast - 30 Days FREE Trial	$170M	x	0,9x
LadRx Corp	LADX	Unlock Forecast - 30 Days FREE Trial	$M	x	x
Lineage Cell Therapeutics, Inc.	LCTX	Unlock Forecast - 30 Days FREE Trial	$271M	-4,7x	5,6x
LENZ Therapeutics, Inc.	LENZ	Unlock Forecast - 30 Days FREE Trial	$1178M	-6,7x	5,7x
Liminatus Pharma, Inc.	LIMN	Unlock Forecast - 30 Days FREE Trial	$0M	x	x
Lexeo Therapeutics, Inc.	LXEO	Unlock Forecast - 30 Days FREE Trial	$271M	-0,4x	2,0x
Maze Therapeutics, Inc.	MAZE	Unlock Forecast - 30 Days FREE Trial	$1022M	x	3,9x
MeiraGTx Holdings plc	MGTX	Unlock Forecast - 30 Days FREE Trial	$693M	-3,4x	20,9x
Metagenomi, Inc.	MGX	Unlock Forecast - 30 Days FREE Trial	$72M	x	0,4x
Moderna, Inc.	MRNA	Unlock Forecast - 30 Days FREE Trial	$9145M	-3,2x	1,0x
NEUROCRINE BIOSCIENCES INC	NBIX	Unlock Forecast - 30 Days FREE Trial	$14442M	41,5x	5,4x
NKGen Biotech, Inc.	NKGN	Unlock Forecast - 30 Days FREE Trial	$4M	-0,1x	-0,2x
NKGen Biotech, Inc.	NKGNW	Unlock Forecast - 30 Days FREE Trial	$1M	x	0,0x
Neumora Therapeutics, Inc.	NMRA	Unlock Forecast - 30 Days FREE Trial	$271M	-3,9x	1,5x
NOVAVAX INC	NVAX	Unlock Forecast - 30 Days FREE Trial	$1416M	3,4x	37,6x
Ocugen, Inc.	OCGN	Unlock Forecast - 30 Days FREE Trial	$298M	-4,3x	18,7x
Omega Therapeutics, Inc.	OMGA	Unlock Forecast - 30 Days FREE Trial	$9M	-0,7x	0,8x
Omega Therapeutics, Inc.	OMGAQ	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
VivoSim Labs, INC.	ONVO	Unlock Forecast - 30 Days FREE Trial	$35M	-0,4x	95,9x
Outlook Therapeutics, Inc.	OTLK	Unlock Forecast - 30 Days FREE Trial	$73M	-0,2x	-2,3x
PALISADE BIO, INC.	PALI	Unlock Forecast - 30 Days FREE Trial	$4M	-0,2x	0,7x
Passage BIO, Inc.	PASG	Unlock Forecast - 30 Days FREE Trial	$23M	-0,6x	0,6x
Vaxcyte, Inc.	PCVX	Unlock Forecast - 30 Days FREE Trial	$4371M	-20,4x	1,4x
BiomX Inc.	PHGE	Unlock Forecast - 30 Days FREE Trial	$14M	1,5x	0,7x
Pluri Inc.	PLUR	Unlock Forecast - 30 Days FREE Trial	$-4M	-1,4x	-9,1x
Protalix BioTherapeutics, Inc.	PLX	Unlock Forecast - 30 Days FREE Trial	$120M	19,1x	2,4x
PharmaCyte Biotech, Inc.	PMCB	Unlock Forecast - 30 Days FREE Trial	$7M	-2,6x	0,2x
Prime Medicine, Inc.	PRME	Unlock Forecast - 30 Days FREE Trial	$547M	-1,5x	9,0x
PROKIDNEY CORP.	PROK	Unlock Forecast - 30 Days FREE Trial	$-70M	x	0,0x
Poseida Therapeutics, Inc.	PSTX	Unlock Forecast - 30 Days FREE Trial	$926M	-9,6x	10,6x
Pelthos Therapeutics Inc.	PTHS	Unlock Forecast - 30 Days FREE Trial	$M	x	x
QIAGEN N.V.	QGEN	Unlock Forecast - 30 Days FREE Trial	$10175M	x	2,9x
Quince Therapeutics, Inc.	QNCX	Unlock Forecast - 30 Days FREE Trial	$86M	-1,7x	7,4x
Replimune Group, Inc.	REPL	Unlock Forecast - 30 Days FREE Trial	$932M	-3,8x	2,2x
REPLIGEN CORP	RGEN	Unlock Forecast - 30 Days FREE Trial	$6531M	8219,1x	3,3x
REGENXBIO Inc.	RGNX	Unlock Forecast - 30 Days FREE Trial	$473M	-1,8x	2,2x
Relay Therapeutics, Inc.	RLAY	Unlock Forecast - 30 Days FREE Trial	$685M	-2,0x	1,0x
Revolution Medicines, Inc.	RVMD	Unlock Forecast - 30 Days FREE Trial	$7134M	-11,1x	3,4x
Revolution Medicines, Inc.	RVMDW	Unlock Forecast - 30 Days FREE Trial	$16M	x	0,0x
RECURSION PHARMACEUTICALS, INC.	RXRX	Unlock Forecast - 30 Days FREE Trial	$2091M	-4,7x	2,3x
SAB Biotherapeutics, Inc.	SABS	Unlock Forecast - 30 Days FREE Trial	$24M	-2,3x	1,1x
SAB Biotherapeutics, Inc.	SABSW	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
Sana Biotechnology, Inc.	SANA	Unlock Forecast - 30 Days FREE Trial	$766M	-2,1x	6,3x
Scilex Holding Co	SCLX	Unlock Forecast - 30 Days FREE Trial	$62M	-0,4x	-0,3x
Scilex Holding Co	SCLXW	Unlock Forecast - 30 Days FREE Trial	$25M	x	-0,1x
Scinai Immunotherapeutics Ltd.	SCNI	Unlock Forecast - 30 Days FREE Trial	$9674M	-287,8x	1231,2x
SANGAMO THERAPEUTICS, INC	SGMO	Unlock Forecast - 30 Days FREE Trial	$131M	-1,6x	6,7x
Solid Biosciences Inc.	SLDB	Unlock Forecast - 30 Days FREE Trial	$495M	-0,9x	1,7x
Silexion Therapeutics Corp	SLXN	Unlock Forecast - 30 Days FREE Trial	$4M	x	34,5x
Silexion Therapeutics Corp	SLXNW	Unlock Forecast - 30 Days FREE Trial	$866M	x	-189,1x
Senti Biosciences, Inc.	SNTI	Unlock Forecast - 30 Days FREE Trial	$51M	-1,1x	1,3x
Scholar Rock Holding Corp	SRRK	Unlock Forecast - 30 Days FREE Trial	$4069M	-18,5x	13,0x
Surrozen, Inc./DE	SRZN	Unlock Forecast - 30 Days FREE Trial	$105M	-0,5x	2,2x
Surrozen, Inc./DE	SRZNW	Unlock Forecast - 30 Days FREE Trial	$0M	x	0,0x
SUTRO BIOPHARMA, INC.	STRO	Unlock Forecast - 30 Days FREE Trial	$90M	-1,0x	-2,5x
SpringWorks Therapeutics, Inc.	SWTX	Unlock Forecast - 30 Days FREE Trial	$3539M	-9,9x	8,5x
Protara Therapeutics, Inc.	TARA	Unlock Forecast - 30 Days FREE Trial	$131M	-2,1x	0,9x
Tarsus Pharmaceuticals, Inc.	TARS	Unlock Forecast - 30 Days FREE Trial	$2084M	-12,4x	6,3x
TC BioPharm (Holdings) plc	TCBP	Unlock Forecast - 30 Days FREE Trial	$37M	x	34,5x
TC BioPharm (Holdings) plc	TCBPW	Unlock Forecast - 30 Days FREE Trial	$1M	x	1,0x
TC BioPharm (Holdings) plc	TCBPY	Unlock Forecast - 30 Days FREE Trial	$13M	x	12,0x
TScan Therapeutics, Inc.	TCRX	Unlock Forecast - 30 Days FREE Trial	$248M	-4,6x	1,4x
BIO-TECHNE Corp	TECH	Unlock Forecast - 30 Days FREE Trial	$8155M	75,2x	4,0x
Tectonic Therapeutic, Inc.	TECX	Unlock Forecast - 30 Days FREE Trial	$314M	-8,9x	1,1x
Instil Bio, Inc.	TIL	Unlock Forecast - 30 Days FREE Trial	$182M	-1,1x	1,3x
Tenaya Therapeutics, Inc.	TNYA	Unlock Forecast - 30 Days FREE Trial	$184M	-2,5x	1,9x
Tourmaline Bio, Inc.	TRML	Unlock Forecast - 30 Days FREE Trial	$1225M	-3,5x	4,7x
Turnstone Biologics Corp.	TSBX	Unlock Forecast - 30 Days FREE Trial	$8M	-0,1x	0,6x
Taysha Gene Therapies, Inc.	TSHA	Unlock Forecast - 30 Days FREE Trial	$871M	-3,0x	3,5x
TITAN PHARMACEUTICALS INC	TTNP	Unlock Forecast - 30 Days FREE Trial	$8M	-0,5x	4,5x
Tevogen Bio Holdings Inc.	TVGN	Unlock Forecast - 30 Days FREE Trial	$168M	x	-29,3x
Tevogen Bio Holdings Inc.	TVGNW	Unlock Forecast - 30 Days FREE Trial	$11M	x	-1,9x
Twist Bioscience Corp	TWST	Unlock Forecast - 30 Days FREE Trial	$1523M	-12,6x	3,2x
Voyager Acquisition Corp./Cayman Islands	VACH	Unlock Forecast - 30 Days FREE Trial	$-1436M	x	0,0x
Voyager Acquisition Corp./Cayman Islands	VACHU	Unlock Forecast - 30 Days FREE Trial	$-1585M	x	0,0x
Vericel Corp	VCEL	Unlock Forecast - 30 Days FREE Trial	$1623M	228,4x	5,3x
Vigil Neuroscience, Inc.	VIGL	Unlock Forecast - 30 Days FREE Trial	$384M	-1,1x	9,3x
Vir Biotechnology, Inc.	VIR	Unlock Forecast - 30 Days FREE Trial	$694M	-2,0x	0,7x
VivoSim Labs, INC.	VIVS	Unlock Forecast - 30 Days FREE Trial	$3M	x	0,3x
Vor Biopharma Inc.	VOR	Unlock Forecast - 30 Days FREE Trial	$246M	-0,6x	3,9x
Vaxart, Inc.	VXRT	Unlock Forecast - 30 Days FREE Trial	$87M	-0,9x	2,7x
Voyager Therapeutics, Inc.	VYGR	Unlock Forecast - 30 Days FREE Trial	$248M	570,6x	1,0x
WINDTREE THERAPEUTICS INC /DE/	WINT	Unlock Forecast - 30 Days FREE Trial	$18M	-0,4x	4,2x
X4 Pharmaceuticals, Inc	XFOR	Unlock Forecast - 30 Days FREE Trial	$8M	6,4x	0,4x
Zivo Bioscience, Inc.	ZIVO	Unlock Forecast - 30 Days FREE Trial	$57M	-31,3x	-2,0x
Zura Bio Ltd	ZURA	Unlock Forecast - 30 Days FREE Trial	$131M	5,0x	0,9x

Häufig gestellte Fragen - SAB Biotherapeutics, Inc. Aktienprognose

Wie genau sind die SAB Biotherapeutics, Inc.-Aktienprognosen?

Our AI model demonstrates 21% historical accuracy for SABS predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

Welche Faktoren beeinflussen SAB Biotherapeutics, Inc. Aktienkursprognosen?

Unsere Analyse berücksichtigt die Finanzkennzahlen von SAB Biotherapeutics, Inc., Life Sciences Branchentrends, die Marktstimmung, technische Indikatoren, Ertragsdaten und makroökonomische Faktoren, die die Aktienperformance beeinflussen.

Ist SAB Biotherapeutics, Inc. eine gute Investition im Jahr 2025?

Nach unserer KI-Analyse zeigt SAB Biotherapeutics, Inc. Potenzial für verschiedene Marktszenarien. Berücksichtigen Sie Ihre Risikotoleranz, Ihren Anlagezeitraum und die Diversifizierung Ihres Portfolios, bevor Sie Anlageentscheidungen treffen.

Wie oft werden die SAB Biotherapeutics, Inc.-Prognosen aktualisiert?

SAB Biotherapeutics, Inc. Aktienprognosen werden täglich auf der Grundlage von Echtzeit-Marktdaten aktualisiert, um sicherzustellen, dass Sie die aktuellsten KI-gestützten Vorhersagen und Investitionseinblicke erhalten.

Möchten Sie eine erweiterte SAB Biotherapeutics, Inc.-Analyse?

Schalten Sie Premium-Funktionen wie detaillierte Kursziele, Risikobewertungen, Portfolio-Optimierung und Echtzeit-Warnungen für SAB Biotherapeutics, Inc. Aktien frei.

🎯 Premium-Analyse erhalten 📊 Mehr Aktien erforschen

Mein Portfolio

Investitions-Dashboard

Laden Sie Ihr Portfolio...

Cookie Preferences

Cookie Settings

Essential Cookies

Analytics Cookies

Herzlich willkommen!

SAB Biotherapeutics, Inc. (SABS) AI-Aktienkursprognose & Investitionsanalyse ⛶Vollbild

SAB Biotherapeutics, Inc. Aktienkurs-Chart und technische Analyse